

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2043	Application Number: 09/620,174
		APR 16 2004 Applicant: Tuszynski, et al.	
		Filing Date: 07/19/2000	Group Art Unit: 1633

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
EDL	A1	01/21/92	5,082,670	Gage et al.			
	A2	06/25/96	5,529,774	Barba et al.			
	A3	07/22/97	5,650,148	Gage et al.			
	A4	11/04/97	5,683,695	Shen et al.			
	A5	05/26/98	5,756,312	Weiner et al.			
	A6	06/09/98	5,762,926	Gage et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
UNL	A7*	06/28/90	WO 90/06757	PCT			

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
UNL	A8*	Armelin et al., "Pituitary extracts and steroid hormones in the control of 3T3 cell growth" <u>Proc. Natl. Acad. Sci.</u> (1973) 70:2702-6.
	A9*	Banerji et al., "Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences" <u>Cell</u> (1981) 27:299-308.
	A10*	Benoist et al., "In vivo sequence requirements of the SV40 early promoter region" <u>Nature</u> (1981) 290:304-10.
	A11*	Blesch et al., "Ex vivo gene therapy for Alzheimer's disease and spinal cord injury" <u>Clinical Neuroscience</u> (1996) 3:268-274.
	A12*	Borsani et al., "cDNA sequence of human beta-NGF" <u>Nucleic Acids Res.</u> (1990) 18:4020.
	A13*	Breathnach et al., "Organization and expression of eucaryotic split genes coding for proteins" <u>Ann. Rev. Biochem.</u> (1981) 50:349-83.
	A14*	Chen et al., "Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA" <u>BioTechniques</u> (1988) 6:632-8.
	A15*	Chen et al., "High-efficiency transformation of mammalian cells by plasmid DNA" <u>Mol. Cell. Biol.</u> (1987) 7:2745-52.
	A16*	Chua et al., "Tumor necrosis factor-alpha induces mRNA for collagenase and TIMP in human skin fibroblasts" <u>Connect. Tissue Res.</u> (1990) 25:161-170.
	A17*	Codner et al., "Distribution of NGF delivered into the rat CNS by either grafted NGF-secreting fibroblasts, intraparenchymal (IP) injections, or IP-infusions" <u>Society for Neuroscience</u> (1997) 23:53 Abstract 29.5.

.1 EXAMINER:	DATE CONSIDERED:
12/16/04 1/18/05	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2043	Application Number: 09/620,174
		APR 26 2004 O I P E JC37 F C	
		Applicant: Tuszynski, et al.	
		Filing Date: 07/19/2000	Group Art Unit: 1633

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
LJL	A18*	Corden et al., "Promoter sequences of eukaryotic protein-coding genes." <u>Science</u> (1980) <u>209</u> :1406-14.
	A19*	DePamphilis et al., "Microinjecting DNA into mouse ova to study DNA replication and gene expression and to produce transgenic animals" <u>BioTechniques</u> (1988) <u>6</u> :662-80.
	A20*	de Wet et al., "The mRNAs for the pro-alpha 1(I) and pro-alpha 2(I) chains of type I procollagen are translated at the same rate in normal human fibroblasts and in fibroblasts from two variants of osteogenesis imperfecta with altered steady state ratios of the two mRNAs" <u>J. Biol. Chem.</u> (1983) <u>258</u> :14385-9.
	A21*	Elias et al., "Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma" <u>Ann. N.Y. Acad. Sci.</u> (1990) <u>580</u> :233-244.
	A22*	Felgner et al., "Cationic liposome mediated transfection" <u>Proc. West. Pharmacol. Soc.</u> (1989) <u>32</u> :115-21.
	A23*	Felgner et al., "Cationic liposome mediated transfection" <u>Focus.</u> (1989) <u>11</u> :21-25.
	A24*	Felgner et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure" <u>Proc. Natl. Acad. Sci.</u> (1987) <u>84</u> :7413-7.
	A25*	Fraley et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids" <u>Trends Biochem. Sci.</u> (1981) <u>6</u> :77-80.
	A26*	Fromm et al., "Deletion mapping of DNA regions required for SV40 early region promoter function in vivo" <u>J. Mol. Appl. Genet.</u> (1982) <u>1</u> :457-81.
	A27*	Gruss et al., "Simian virus 40 tandem repeated sequences as an element of the early promoter" <u>Proc. Natl. Acad. Sci.</u> (1981) <u>78</u> :943-7.
	A28*	Hefti et al., "Nerve growth factor and Alzheimer's disease" <u>Ann. Neurol.</u> (1986) <u>20</u> :275-81.
	A29*	Higgins et al., "NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease" <u>Exp. Neurol.</u> (1989) <u>106</u> :222-36.
	A30*	Horellou et al., "Adenovirus-mediated gene transfer to the central nervous system for Parkinson's Disease" <u>Experimental Neurobiology</u> (1997) <u>144</u> :131-8.
	A31*	Jolly et al., "Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene" <u>Nucleic Acids Res.</u> (1983) <u>11</u> :1855-1872.
	A32*	Kobayashi et al., "Morphometric study on the CHS of the nucleus basalis of Meynert in Alzheimer's disease" <u>Mol. Chem. Neuropathol.</u> (1991) <u>15</u> :193-206.
	A33*	Kordower et al., "The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor" <u>Proc. Natl. Acad. Sci.</u> (1994) <u>91</u> :10898-10902.
	A34*	Lehericy et al., "Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease" <u>J. Comp. Neurol.</u> (1993) <u>330</u> :15-31.
	A35*	Levivier et al., "Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease" <u>The Jo. Of Neuroscience</u> (1995) <u>15</u> :7810-20.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

O I P
APR 26 2004
PATENT AND TRADEMARK OFFICE

<p>Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)</p>			Docket Number: 041673/2043	Application Number: 09/620,174
			Applicant: Tuszynski, et al.	
			Filing Date: 07/19/2000	Group Art Unit: 1633
OTHER DOCUMENTS <i>(including author, title, Date, Pertinent Pages, Etc.)</i>				
Examiner Initials	Ref. No.	Title		
LDL	A36	Mannino et al., "Liposome mediated gene transfer" <u>Biotechniques</u> (1988) <u>6</u> :682-90.		
	A37	Maxam et al., "Sequencing end-labeled DNA with base-specific chemical cleavages" <u>Methods in Enzymology</u> (1980) <u>65</u> :499-560.		
	A38	McCutchan et al., "Enhancement of the infectivity of simian virus 40 deoxy ribonucleic acid with diethylaminoethyl-dextran" <u>J. Natl. Cancer Inst.</u> (1968) <u>41</u> :351-7.		
	A39	Messing et al., "A system for shotgun DNA sequencing" <u>Nucleic Acids Res.</u> (1981) <u>9</u> :309-21.		
	A40	Mesulam et al., "Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey." <u>J. Comp. Neurol.</u> (1983) <u>214</u> :170-197.		
	A41	Moreau et al., "The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants" <u>Nucleic Acids Res.</u> (1981) <u>9</u> :6047-6068.		
	A42	Mufson et al., "Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain" <u>Exp. Neurol.</u> (1989) <u>105</u> :221-32.		
	A43	Mufson et al., "Nerve growth factor receptor expressing human basal forebrain neurons: pathologic alterations in Alzheimer's and Parkinson's disease" <u>Prog. Clin. Biol. Res.</u> (1989) <u>317</u> :401-14.		
	A44	Palmer et al., "Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes" <u>Proc. Natl. Acad. Sci.</u> (1991) <u>88</u> :1330-4.		
	A45	Potter et al., "Electroporation in biology: methods, applications, and instrumentation" <u>Anal. Biochem.</u> (1988) <u>174</u> :361-73.		
	A46	Prockop et al., "Heritable diseases of collagen" <u>N. Eng. J. Med.</u> (1984) <u>311</u> :376-86.		
	A47	Raymon et al., "Application of ex vivo gene therapy in the treatment of Parkinson's disease" <u>Experimental Neurobiology</u> (1997) <u>144</u> :82-91.		
	A48	Rossi et al., "Identification of a cell-specific transcriptional enhancer in the first intron of the mouse alpha 2 (type I) collagen gene" <u>Proc. Natl. Acad. Sci.</u> (1987) <u>84</u> :5590-4.		
	A49	Schmidt et al., "Regulation of a collagen promoter by the product of viral mos oncogene" <u>Nature</u> (1985) <u>314</u> :286-9.		
	A50	Seliger et al., "Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription" <u>J. Virology</u> (1988) <u>62</u> :619-21.		
	A51	Seliger et al., "Tumor necrosis factor-alpha affects LTR-controlled oncogene expression in transformed mouse fibroblasts at the post-transcriptional level" <u>J. Immunol.</u> (1988) <u>141</u> :2138-44.		
	A52	Shvaloff et al., "Lines of therapeutic research in Alzheimer's disease" <u>Psychopharmacology Bulletin</u> (1996) <u>32</u> :343-52..		
	A53	Smith et al., "Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy" <u>Proc. Natl. Acad. Sci.</u> (1999) <u>96</u> :10893-8.		
	A54	Smith et al., "Characterization of collagen synthesized by normal and chemically transformed rat liver epithelial cell lines" <u>Biochem.</u> (1980) <u>19</u> :1820-5.		
EXAMINER: <i>[Signature]</i>			DATE CONSIDERED: <i>7/19/05</i>	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2043	Application Number: 09/620,174
		Applicant: Tuszynski, et al.	
		Filing Date: 07/19/2000	Group Art Unit: 1633

OTHER DOCUMENTS*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
LN	A55	Toneguzzo et al., "Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells" <u>Molec. Cell. Biol.</u> (1986) 6:703-6.
	A56	Tuszynski et al., "Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration" <u>Gene Therapy</u> (1996) 3:305-14.
	A57	Tuszynski et al., "Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain" <u>Ann. Neurol.</u> (1991) 30:625-36.
	A58	Tuszynski et al., "Somatic gene therapy for nervous system disease" <u>Ciba Foundation Symposium 196, Growth factors as drugs for neurological and sensory disorders</u> (1996) 196:85-97.
	A59	Tuszynski et al., "The chronically injured spinal cord exhibits responsiveness to NGF delivered locally by gene therapy" <u>Society for Neuroscience (1995) 21:1562 Abstract 613.3.</u>
	A60	Ullrich et al., "Human beta-nerve growth factor gene sequence highly homologous to that of a mouse" <u>Nature</u> (1983) 303:821-5.
	A61	Wolff et al., "Expression of retrovirally transduced genes in primary cultures of rat hepatocytes" <u>Proc. Natl. Acad. Sci.</u> (1987) 84:3344-8.

EXAMINER:	<i>[Handwritten signature]</i>	DATE CONSIDERED:	<i>7/19/05</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 041673-2043	SERIAL NO. 09/620, 174
INFORMATION DISCLOSURE CITATION <i>6/26/2004</i> (Use several sheets if necessary)		APPLICANT Tuszynski, Mark H.		
		FILING DATE 07/19/2000	GROUP ART UNIT 1633	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>LD</i>	A1 *	Kojima, et al., "Adenovirus-Mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain," <i>Biochemical and Biophysical Research Communications</i> , <u>238</u> :569-573 (1997)
	A2 *	Roberts, et al., "Effects of NGF-Secreting Genetically Modified Cell Grafts on Cholinergic Neuronal Morphology and Gocnition in Aged Primates," <i>Soc. For Neuroscience Abstracts</i> , <u>21</u> (2):613.8 (1995)
	A3 *	Yang, et al., "Gene Therapy for Central Nervous System Injury: The Use of Cationic Liposomes: An Invited Review," <i>Journal of Neurotrauma</i> , <u>14</u> (5):281-297 (1997)
<i>↓</i>	A4 *	Zlokovic, et al., "Cellular and Molecular Neurosurgery: Pathways From Concept to Reality – Part II: Vector Systems and Delivery Methodologies for Gene Therapy of The Central Nervous System," <i>Neurosurgery</i> , <u>40</u> (4):805-813 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER'S Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE APR 26 2004 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. 041673-2043	SERIAL NO. 09/620, 174
		APPLICANT Tuszynski, Mark H.	
		FILING DATE 07/19/2000	GROUP ART UNIT 1633

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

COL	ATX	Tuszynski, et al., "Targeted Intraparenchymal Delivery of Human NGF by Gene Transfer to the Primate Basal Forebrain for 3 Months Does Not Accelerate β -Amyloid Plaque Disposition," <i>Experimental Neurology</i> , Article No. EN986956 1-10 (1998).

EXAMINER	DATE CONSIDERED
	1/19/05

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.